None
EN
Lenacapavir: There are mounting concerns over transparency in cost
['Ina Skosana', 'Phumzile Mkhungo', 'Sandile Mbili', 'Polotso Thulo', 'Bernard Chiguvare', 'Thomo Nkgadima', 'Health-E News', '.Pp-Multiple-Authors-Boxes-Wrapper.Pp-Multiple-Authors-Layout-Boxed.Multiple-Authors-Target-The-Content .Pp-Author-Boxes-Avatar Img Width', 'Important Height', 'Important']
Health-e News
Lenacapavir: There are mounting concerns over transparency in costSouth Africa may be able to start rolling out lenacapavir (LEN), the twice-yearly HIV prevention jab, in January 2026 – three months earlier than initially planned.
“There is a commitment from The Global Fund of US$29 million ringfenced for lenacapavir over the next two and a half years,” says Buthelezi.
Lack of transparency“We need LEN, but we need transparency,” says Dr Thembisile Xulu.
While delivering the memorandum, Treatment Action Campaign’s Gcinumzi Sawuka said to Phaahla: “Gilead, just like PEPFAR, are bullying South Africa.
At the negotiated price, it was reported by Bhekisisa, around 400,000 people in South Africa will get the jab.
['cost'
'mounting'
'south'
'lenacapavir'
'global'
'gilead'
'million'
'africa'
'need'
'price'
'len'
'concerns'
'transparency'
'fund']